Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.
暂无分享,去创建一个
C. Ching | J. Hicks | A. D. De Marzo | D. Theodorescu | C. Eng | D. Hansel | M. Orloff | E. Hsi | R. Steinle | Eric Platt | J. Harwalker | Swathi Sethu
[1] R. Kahnoski,et al. Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. , 2009, Cancer research.
[2] C. Cordon-Cardo,et al. Inactivation of p53 and Pten promotes invasive bladder cancer. , 2009, Genes & development.
[3] D. Schmidt,et al. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. , 2009, Urology.
[4] B. Wouters,et al. Hypoxia signalling through mTOR and the unfolded protein response in cancer , 2008, Nature Reviews Cancer.
[5] S. Saito,et al. Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. , 2008, European journal of cancer.
[6] R. Abraham,et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. , 2008, Cancer research.
[7] M. Knowles,et al. Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms , 2008, Human molecular genetics.
[8] G. Rassidakis,et al. Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas , 2008, Expert Reviews in Molecular Medicine.
[9] M. You,et al. Bnip3 Mediates the Hypoxia-induced Inhibition on Mammalian Target of Rapamycin by Interacting with Rheb* , 2007, Journal of Biological Chemistry.
[10] Samy Lamouille,et al. Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway , 2007, The Journal of cell biology.
[11] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[12] R. Millikan,et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. , 2007, Urology.
[13] D. Birle,et al. Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts , 2006, Molecular Cancer Therapeutics.
[14] D. Sabatini. mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.
[15] H. Kuwano,et al. Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. , 2006, Oncology reports.
[16] D. Sabatini,et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.
[17] R. Memmott,et al. Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway , 2006, Clinical Cancer Research.
[18] N. Hay,et al. The Akt-mTOR tango and its relevance to cancer. , 2005, Cancer cell.
[19] Xue-Ru Wu. Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.
[20] Wolfgang Eiermann,et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Robert T. Abraham,et al. Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 Is Mediated by p70S6 Kinase* , 2005, Journal of Biological Chemistry.
[22] R Y Ball,et al. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs , 2005 .
[23] C. Moskaluk,et al. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity , 2004, Oncogene.
[24] Andrew K Godwin,et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth , 2004, Oncogene.
[25] S. Liou,et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Howell,et al. A Novel Hypoxia-inducible Factor-independent Hypoxic Response Regulating Mammalian Target of Rapamycin and Its Targets* , 2003, Journal of Biological Chemistry.
[27] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[28] J. Blenis,et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[29] Holger Moch,et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade , 2001, The Journal of pathology.
[30] P. Steck,et al. Inactivation of MMAC1 in bladder transitional‐cell carcinoma cell lines and specimens , 2000, Molecular carcinogenesis.
[31] C. Eng,et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. , 2000, Journal of the National Cancer Institute.
[32] Johannes Gerdes,et al. The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.
[33] M. Knowles,et al. Somatic mutation of PTEN in bladder carcinoma , 1999, British Journal of Cancer.
[34] I. Tannock,et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] François Radvanyi,et al. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder , 1997, Oncogene.
[36] Jing Li,et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.
[37] M. Knowles,et al. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. , 1993, Oncogene.
[38] S. Fosså,et al. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. , 1987, The Journal of urology.